Showing results (21-30 of 38) with videos related to
Sort By:
Pageof 4
Case Reports in Oncology|March 8, 2013
Response of meningeal carcinomatosis from breast cancer to capecitabine monotherapy: a case reportYumi Tanaka, Shoji Oura, Tatsuya Yoshimasu, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 4, 2003
[Histoculture drug response assay (HDRA) guided induction concurrent chemoradiotherapy for mediastinal node-positive non-small cell lung cancer]Tatsuya Yoshimasu, Shoji Oura, Issei Hirai, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 28, 2005
[Cut-off level of docetaxel, paclitaxel and gemcitabine in histoculture drug response assay for non-small cell lung cancer]Tatsuya Yoshimasu, Shoji Oura, Issei Hirai, et al.The Japanese Journal of Thoracic and Cardiovascular Surgery : Official Publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai Zasshi|April 16, 2003
Intrapleural administration of a large amount of diluted fibrin glue for intractable pneumothorax. A clinical study based on 57 cases: including 2 unsuccessful casesTakahiro Kinoshita, Shinichiro Miyoshi, Takaomi Suzuma, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 18, 2011
Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancerTatsuya Yoshimasu, Shoji Oura, Fuminori Ohta, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 17, 2012
[The importance of p53 and ras mutation as predictive markers for adjuvant chemotherapy in non-small-cell lung cancer]Yoshimitsu Hirai, Yukio Shimizu, Shoji Oura, et al.Internal Medicine (Tokyo, Japan)|February 17, 2009
Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancerYoshiki Hayashi, Hideyuki Kuriyama, Hajime Umezu, et al.General Thoracic and Cardiovascular Surgery|March 13, 2009
Histoculture drug response assay for gefitinib in non-small-cell lung cancerTatsuya Yoshimasu, Fuminori Ohta, Shoji Oura, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 21, 2018
[Application of Bevacizumab beyond Progressive Disease in Patients with Lung Cancer Recurrence after Surgery]Tatsuya Yoshimasu, Shoji Oura, Mitsumasa Kawago, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 19, 2009
[Safety and efficacy of weekly paclitaxel followed by FEC100 as primary systemic therapy for breast cancer]Koma Naito, Shoji Oura, Tatsuya Yoshimasu, et al.Pageof 4